1181-Interferon-α Gene Therapy for Glioblastoma

This study details a phase 1 trial of Temferon, an innovative gene therapy designed to treat glioblastoma by utilizing genetically modified stem cells. The treatment engineers a patient's own cells to deliver interferon-α2 directly to the tumor microenvironment, effectively bypassing the toxicities associated with systemic administration. Researchers found the therapy to be safe and tolerable, with no dose-limiting toxicities observed across twenty-four subjects. Data indicates that Temferon successfully reprograms the immune environment, shifting suppressive macrophages into an inflammatory state that promotes antitumor activity. While the trial primarily focused on safety, results showed prolonged disease stabilization and recruitment of tumor-reactive T cells within the brain. Ultimately, the study suggests that this HSPC-based platform offers a feasible new strategy for treating immunologically "cold" brain malignancies.References:Gentner B, Eoli M, Farina F, et al. Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial[J]. Nature Medicine, 2026: 1-11.前往小宇宙评论区与主播互动